At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 176 enrolled
Drug / intervention
PF-03187207 and Latanoprost Vehicle +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, 28 Day Parallel-Group, Double-Masked, Dose-Finding Study Comparing the Safety and Efficacy of PF-03187207 to Latanoprost
In Brief
A Phase 2 clinical trial evaluating PF-03187207 and Latanoprost Vehicle and Latanoprost 0.005% and PF-03187207 Vehicle for Primary Open Angle Glaucoma and 3 related conditions. Completed, enrolled 176 participants across 19 sites.
Detailed Summary
This study will evaluate the safety and efficacy of PF 03187207.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrimary Open Angle Glaucoma, Ocular Hypertension, Pigmentary Glaucoma, Pseudoexfoliative Glaucoma
CountriesUnited States
CollaboratorsNicOx Inc.
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 2007
Enrollment StartMar 2007
Primary CompletionFeb 2008
Study CompletionJul 2008
TodayJul 2026
First PostedMar 1, 2007
Enrollment StartMar 1, 2007
Primary CompletionFeb 1, 2008
Study CompletionJul 1, 2008
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 19.3 years ago
Interventions
PF-03187207 and Latanoprost Vehicledrug
Latanoprost 0.005% and PF-03187207 Vehicledrug